2. Signaling Pathways
  3. Immunology/Inflammation
  4. LAG-3
  5. LAG-3 Inhibitor

LAG-3 Inhibitor

LAG-3 Inhibitors (5):

Cat. No. Product Name Effect Purity
  • HY-144987
    RBN013209
    		Inhibitor 98.87%
    RBN013209 is an orally active small molecule inhibitor of CD38 with an IC50 of 0.01 to 0.1 μM for human CD38. RBN013209 prevents the conversion of extracellular NAD+ to ADPR or cADPR in tumor cells and PBMCs. RBN013209 can be used in the study of tumor. In addition, RBN013209 enables CAR-T cells to maintain the naive state and central memory state, and decreases the expression of cell activation markers and exhaustion-related inhibitory receptors.
  • HY-P99922
    Encelimab
    		Inhibitor
    Encelimab is an anti-LAG3 antibody. Encelimab blocks the interaction between LAG-3 and MHC II, and enhances T-cell activation. Encelimab alone or in combination with an anti-PD-1 antibody reduces tumor size in a lymphoma mice model (A20 cell xenograft).
  • HY-P10835
    LAG-3 cyclic peptide inhibitor C25
    		Inhibitor
    LAG-3 cyclic peptide inhibitor C25 is a LAG-3 inhibitor. LAG-3 cyclic peptide inhibitor C25 has a high affinity with human LAG-3 protein with a Kd value of 0.66 μM. LAG-3 cyclic peptide inhibitor C25 can block the interaction of LAG-3 with HLA-DR (MHC-II) and activate CD8+ T cells. LAG-3 cyclic peptide inhibitor C25 can be used in the study of cancer.
  • HY-P990195
    Anti-Mouse MHC Class I (H-2) Antibody (M1/42.3.9.8)
    		Inhibitor
    Anti-Mouse MHC Class I (H-2) Antibody (M1/42.3.9.8) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse MHC Class I.
  • HY-164308
    SA-15-P
    		Inhibitor
    SA-15-P inhibits LAG-3/MHCII and LAG-3/FGL1 interactions with IC50 values of 4.21 and 6.52 μM respectively. LAG-3/MHCII interaction is a target for immunotherapies.